Table 2 Patient and procedure characteristics for visualization and non-visualization
From: An analysis of SPECT/CT non-visualization of sentinel lymph nodes in renal tumors
Visualization N and % or median and IQR | Non-visualization N and % or median and IQR | |
|---|---|---|
Number of patients | 46 (63%) | 27 (37%) |
Gender | ||
Female | 22 (47.8%) | 14 (51.9%) |
Male | 24 (52.2%) | 13 (48.1%) |
Age, years (median, IQR) | 56 (49–63) | 62 (54–70) |
Age above 59 years | 21 (45.7%) | 17 (63%) |
Age below 59 years | 25 (54.3%) | 10 (37%) |
BMI (median, IQR) | 27 (23–30) | 26 (24–32) |
Size of the tumor (cm) (median, IQR) | 5.6 cm (4.1–7.0) | 6.5 cm (5.0–8.0) |
Tumor location | ||
Side | ||
Right | 23 (50%) | 13 (48.1%) |
Left | 23 (50%) | 14 (51.9%) |
Polarity | ||
Upper pole | 12 (26.1%) | 3 (11.1%) |
Intermedial pole | 17 (37%) | 14 (51.9%) |
Lower pole | 17 (37%) | 10 (37.1%) |
Axial position | ||
Posterior | 19 (41.3%) | 14 (51.9%) |
Anterior | 27 (58.7%) | 13 (48.1%) |
Renal score | ||
Low risk | 7 (15.2%) | 5 (18.5%) |
Moderate risk | 11 (23.9%) | 7 (25.9%) |
High risk | 28 (60.9%) | 15 (55.6%) |
pTstage | ||
T1a | 9 (19.6%) | 2 (7.4%) |
T1b | 26 (56.5%) | 17 (63%) |
T2a | 4 (8.7%) | 4 (14.8%) |
T2b | 2 (4.3%) | 1 (3.7%) |
T3a | 5 (10.9%) | 3 (11.1%) |
pNstage | ||
N0 | 44 (95.7%) | 21 (77.8%) |
N1 | 1 (2.2%) | 1 (3.7%) |
Nx | 1 (2.2%) | 5 (18.5%) |
Histology | ||
ccRCC | 30 (65.2%) | 22 (81.5%) |
Pap I | 5 (10.9%) | 2 (7.4%) |
Pap II | 3 (6.5%) | 1 (3.7%) |
Chromophobe | 4 (8.7%) | 1 (3.7%) |
Oncocytoma | 3 (6.5%) | 0 |
Fibrous tumor | 1 (2.2%) | 0 |
NOS | 0 | 1 (3.7%) |
Fuhrman grade | ||
I | 4 (8.9%) | 4 (14.8%) |
II | 12 (26.7%) | 12 (44.4%) |
III | 13 (28.9%) | 3 (11.1%) |
IV | 0 | 4 (14.8%) |
NA | 17 (37.8%) | 4 (14.8%) |
Leibovich score | ||
Low | 18 (39%) | 10 (37%) |
Intermediate | 13 (28.3%) | 9 (33.3%) |
High | 4 (8.7%) | 4 (14.8%) |
NA | 11 (23.9%) | 4 (14.8%) |
Lymphovascular invasion | ||
Yes | 4 (8.7%) | 2 (7.4%) |
No | 42 (91.3%) | 25 (92.6%) |
Necrosis in histology | ||
Yes | 16 (34.8%) | 15 (55.6%) |
No | 30 (65.2%) | 12 (44.4%) |
Necrosis on imaging | ||
Yes | 4 (8.7%) | 5 (18.5%) |
No | 42 (91.3%) | 22 (81.5%) |
SN radioactivity detected with γ-probe and camera | ||
Yes | 40 (87.0%) | 5 (18%) |
No | 6 (13.0%) | 22 (81.5%) |
Injection modality | ||
UH | 45 (97.8%) | 27 (100%) |
CT | 1 (2.2%) | 0 |
99mTc dose, MBq (median, IQR) | 209 (187–222) | 212 (196–218) |
Number of injections | ||
1 injection | 27 (58.7%) | 18 (66.7%) |
2 injections | 18 (39.1%) | 9 (33.3%) |
3 injections | 1 (2.2%) | 0 |
Spillage | ||
Yes | 13 (28.3%) | 4 (14.8%) |
No | 30 (65.2%) | 17 (63%) |
NA | 3 (6.5%) | 6 (22.2%) |
Depot properly Injected | ||
Yes | 30 (65.2%) | 14 (51.9%) |
No | 2 (4.3%) | 1 (3.7%) |
NA | 14 (30.4%) | 12 (44.4%) |
Anterior depot | 19 (41.3%) | 11 (40.7%) |
Posterior depot | 18 (39.1%) | 9 (33.3%) |
Not anterior nor posterior | 9 (19.6%) | 7 (25.9%) |
Number of depots | ||
1 | 26 (59.1%) | 13 (48.1%) |
2 | 17 (38.6%) | 5 (18.5%) |
3 | 0 | 2 (7.4%) |
Data not available | 3 (6.5%) | 7 (25.9%) |
SN visualization | ||
On early planar scintigraphy | 5 (10.9%) | NA |
On late planar scintigraphy | 9 (19.6%) | |
On early planar scintigraphy combined with SPECT/CT | 32 (69.6%) | |
SN number on imaging (mean, IQR, sum) | 1.1 (0–2, 80) | NA |
SN number harvested at surgery (mean, IQR, sum) | 2.1 (0–3, 155) | NA |
Non SN number harvested at surgery (mean, IQR, sum) | 3.0 (0–4, 220) | NA |
Time between injection and 1st imaging in minutes (median, IQR) | 28 min (15 min–65 min) | 28 min (15 min–1 h 5 min) |
Time between injection and 2nd Imaging in minutes (median, IQR) | 149 min (175 min–188 min) | 182 min (139 min–194 min) |
Kidney/liver activity ratio at early scintigraphy (median, IQR) | 22.4 (4.0–51.6) | 6.6 (1.5–17.6) |
Kidney/liver activity ratio at late scintigraphy (median, IQR) | 10.7 (3.7–26.9) | 3.6 (1.5–11.4) |